Clinical trial
A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
NCT06475742 is registered in ClinicalTrials.gov with Viatris Innovation GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Open-label, Single-arm, Extension Study to Evaluate the Long-term Safety and Tolerability of Cenerimod in Adult Subjects With Moderate-to-Severe Systemic Lupus Erythematosus (SLE) on Top of Background Therapy
- Lead sponsor
- Viatris Innovation GmbH
- Phase
- Phase 3
- Overall status
- Enrolling by invitation
- Start date
- July 30, 2024
- Completion date
- September 30, 2032
- Enrollment
- 680 (estimated)
- Sites
- 122
Conditions
As the registry lists them; a condition with its own page is linked.